About Nanoligent
Nanoligent is a company based in Barcelona (Spain) founded in 2017 by M Rodriguez, Ramon Mangues, Antonio Villaverde, and Esther Vazquez. Nanoligent has raised $15.05 million across 3 funding rounds from investors including i&i Bio, Italian Angels for Growth and AVANTECA. Nanoligent offers products and services including Targeted Protein Conjugates and Drug Development Platform. Nanoligent operates in a competitive market with competitors including Certis Oncology Solutions, Xentech and Rincon Bio, among others.
- Headquarter Barcelona, Spain
- Founders M Rodriguez, Ramon Mangues, Antonio Villaverde, Esther Vazquez
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nanoligent S.L.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15.05 M (USD)
in 3 rounds
-
Latest Funding Round
$13.92 M (USD), Series A
Oct 10, 2025
-
Investors
i&i Bio
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nanoligent
Nanoligent offers a comprehensive portfolio of products and services, including Targeted Protein Conjugates and Drug Development Platform.
Engineers nanoparticles for precise cancer drug delivery and targeting
Designs new precision medicines for oncology and other diseases
People of Nanoligent
Unlock access to complete
Unlock access to complete
Funding Insights of Nanoligent
Nanoligent has successfully raised a total of $15.05M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $13.92 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nanoligent
Nanoligent has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include i&i Bio, Italian Angels for Growth and AVANTECA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
A network of business angels is formed to support innovative startups.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Nanoligent
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nanoligent
Investment portfolio details for Nanoligent
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nanoligent
Detailed financials for Nanoligent
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nanoligent Comparisons
Peer comparison for Nanoligent
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nanoligent
Nanoligent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Certis Oncology Solutions, Xentech and Rincon Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Oncology-based in-vivo drug development services are provided.
|
|
| Locked | Locked | Locked |
Patient-derived xenograft models for preclinical oncology research are provided.
|
|
| Locked | Locked | Locked |
Pre-clinical CRO for in vivo cancer efficacy studies using xenograft and syngeneic models.
|
Detailed competitors of Nanoligent
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nanoligent
Complete news archive for Nanoligent
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nanoligent
Nanoligent was founded in 2017 and raised its 1st funding round 5 years after it was founded.
Nanoligent is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Montserrat Cano Biosca is the current CEO of Nanoligent.
Nanoligent is a funded company, having raised a total of $15.05M across 3 funding rounds to date.
Nanoligent was founded in 2017 and is based in Barcelona, Spain. Preclinical services focused on oncology drug development are offered, supporting research and testing phases for pharmaceutical clients. Operations center on biological and pharmacological evaluations, including in vitro and in vivo models. Expertise in nanotechnology applications is utilized to advance therapeutic candidates in the biotech sector. Leadership includes co-founders with backgrounds in oncology and molecular biology.
Nanoligent's top competitors include Certis Oncology Solutions, Xentech and Rincon Bio.
Nanoligent offers Targeted Protein Conjugates and Drug Development Platform.
Nanoligent has 4 investors. Key investors include i&i Bio, Italian Angels for Growth, AVANTECA, and Inveready.